International agreement statements for monitoring disease activity in Crohn's disease patients The results of the IBD AHEAD 2011 project
Review articleGastroent Hepatol 2012; 66(2): 136-141.
Summarypdf Milan LukášStandard diagnostic and therapeutic process of IBD-associated anaemia
GuidelinesGastroent Hepatol 2012; 66(4): 280-285.
Summarypdf Luděk Hrdlička, Pavel Kohout, Martin Liberda, Michal Konečný, Milan LukášLong-term Infliximab Maintenance Therapy for Ulcerative Colitis The ACT-1 and ACT-2 Extension Studies
Commented papersGastroent Hepatol 2012; 66(4): 286-288.
pdf Milan LukášGuidelines forthe administration of aminosalicylates in patients with inflammatory bowel diseases
GuidelinesGastroent Hepatol 2012; 66(5): 391-400.
Summarypdf Lucie Prokopová, Dana Ďuricová, Martin Bortlík, Vladimír Zbořil, Milan LukášBudenofalk 2 mg rectal foam represents a major new option in the treatment of patients with ulcerous colitis
Drug profileGastroent Hepatol 2012; 66(5): 413-414.
pdf Milan LukášDoes golimumab extend the spectrum of anti-TNFα inhibitors for inflammatory bowel diseases?
Review articleGastroent Hepatol 2012; 66(6): 465-469.
Summarypdf Milan LukášEditorial board's plans and ideas for the year 2013
EditorialGastroent Hepatol 2013; 67(1): 6-7.
pdf Milan Lukáš, Irena KratochvílováSerum zymogen glycoprotein 2 antibodies (anti-GP2) in patients with inflammatory bowel disease
Original articleGastroent Hepatol 2013; 67(1): 10-16.
Summarypdf Karin Malíčková, Dana Ďuricová, Martin Bortlík, Luděk Hrdlička, Naděžda Machková, Milan Lukáš